Jove
Visualize
Contact Us

Related Experiment Video

Updated: May 21, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Biological prognostic markers in diffuse large B-cell lymphoma.

Anamarija M Perry1, Zdravko Mitrovic, Wing C Chan

  • 1Department of Pathology and Microbiology, Nebraska Medical Center, Omaha 68198-3135, USA.

Cancer Control : Journal of the Moffitt Cancer Center
|June 20, 2012
PubMed
Summary

Novel prognostic markers are needed for diffuse large B-cell lymphoma (DLBCL) to tailor treatments. Current methods are complex and costly, with no consensus on routine use, hindering personalized patient care.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CEACAM1 expression by immunohistochemistry in B-cell lymphomas and plasma cell myeloma.

American journal of clinical pathology·2026
Same author

Association of anesthesiologists' hepato-pancreato-biliary volume and outcomes for other surgeries.

HPB : the official journal of the International Hepato Pancreato Biliary Association·2026
Same author

Incidence and Survival of Gastro-Entero-Pancreatic Neuroendocrine Neoplasms in the Contemporary Era.

JAMA network open·2026
Same author

Challenges in Diagnosing High-grade B-cell Lymphoma, NOS: Poor Interobserver Agreement on Its Morphologic Definition-An LLMPP Study.

The American journal of surgical pathology·2026
Same author

Contemporary short-term post-operative outcomes after resection of entero-pancreatic NETs: a population-based study.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026
Same author

Predicting Days at Home after Elective Surgery for Gastrointestinal Cancer using HOMEDAYS: Prediction Model Development and Internal Validation.

Journal of the American College of Surgeons·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Hematology
  • Oncology
  • Genomics

Background:

  • Emerging therapies for non-Hodgkin lymphoma necessitate advanced prognostic markers.
  • Accurate patient risk stratification is crucial for personalized treatment strategies.

Purpose of the Study:

  • To review established and emerging prognostic markers for diffuse large B-cell lymphoma (DLBCL) in the rituximab era.
  • To highlight the need for clinically applicable prognostic tools in DLBCL management.

Main Methods:

  • Review of current literature on prognostic markers in DLBCL.
  • Discussion of biomarkers assessed by morphology, immunohistochemistry, and molecular techniques.
  • Evaluation of the clinical utility and limitations of various prognostic assessment methods.

More Related Videos

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Related Experiment Videos

Last Updated: May 21, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Main Results:

  • Prognostic markers in DLBCL encompass morphology, immunohistochemistry, gene expression profiling, and next-generation sequencing.
  • Many advanced molecular methods are not routinely used due to cost, complexity, and tissue requirements.
  • Significant institutional variation exists in the assessment of biological prognostic markers.

Conclusions:

  • Ongoing efforts aim to develop reproducible platforms for routine clinical use of prognostic markers.
  • A consensus on routine biological prognostic marker assessment in DLBCL is currently lacking.
  • Future global approaches may enhance understanding of biomarker significance in tumor context for improved patient outcomes.